Resultados: 10

The impact of depression in the Brazilian private healthcare system: patient journey and economic burden study associating claim database and expert’s opinion approach

Matos, Marco Antonio Silva Moreira; Ogata, Alberto; Abdo, Carmita; Gondo, Celso Mitsua; Lodi, Maria Teresa Diniz Velloso; Stefani, Stephen; Bilevicius, Elizabeth.

J. bras. econ. saúde (Impr.); 15 (1), 2023

Objective: The study aimed to describe the profile and economic burden of patients with depression from the perspective of the Brazilian Private Healthcare System (PHS). Methods: A two-step methodological quantitative-qualitative research design was performed: retrospective descriptive analysis of the Or...

Depressão, Saúde Suplementar, Custos e Análise de Custo

Texto completo

The impact of patients with generalized anxiety disorder in the Brazilian Private Healthcare System: a claim database study with expert’s perspective

Matos, Marco Antonio Silva Moreira; Ogata, Alberto; Gondo, Celso Mitsuo; Dieckman, Luiz; Stefani, Stephen; Teng, Chei Tung; Bilevicius, Elizabeth.

J. bras. econ. saúde (Impr.); 15 (1), 2023

This study describes the healthcare resource use and costs associated with anxiety assessing claim database outcomes and expert opinion from the perspective of the Brazilian Private Healthcare System. A retrospective analysis of the Orizon database was conducted, containing claims data of anxiety patient...

Transtornos Fóbicos, Saúde Suplementar, Efeitos Psicossociais da Doença

Texto completo

The impact of COPD on the private healthcare system in Brazil: an economic analysis

Nascimento, Oliver Augusto; Saturnino, Luciana Tarbes Mattana; Santos, Felipe Moares dos; Silva, Danielle Oliveira da; Gazzotti, Mariana Rodrigues; Martins, Franco Chies; Gomes, Ana Luisa Bessa Bacellar; Viana, Karynna Pimentel; Afonso-Cristancho, Rafael; Rodrigues, Claudia Soares.

J. bras. econ. saúde (Impr.); 15 (1), 2023

Objective: To assess healthcare resource utilization and hospitalization costs of patients with chronic obstructive pulmonary disease (COPD) exacerbations in the Brazilian private healthcare system. Methods: A retrospective cohort study, considering data from an administrative database of a private compa...

Doença Pulmonar Obstrutiva Crônica, Custos e Análise de Custo, Saúde Suplementar

Texto completo

Cost of chronic red blood cell transfusion in the Brazilian private healthcare sector from a payer perspective

Magro, Frederico José Bighetti; Ribeiro, Rodrigo Antonini; Sekine, Leo; Marinato, André Fiorin; Samir, Kanaan Nabhan; Stefani, Stephen Doral; Marques Junior, José Francisco Comenalli.

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: In the private healthcare sector in Brazil, the dearth of information regarding transfusion cost may compromise the management of conditions requiring long-term transfusion. Therefore, the present study aimed to estimate the cost of chronic red blood cell (RBC) transfusion in this context. Met...

Transfusão de Sangue, Eritrócitos, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Cost-effectiveness of moderate-to-severe psoriasis biologic treatments in Brazilian private healthcare system: cost-per-responder results derived from a network metanalysis

Carvalho, André Vicente Esteves de; Duarte, Gleison Vieira; Ianhez, Mayra; Silva, Bruno Leonardo; Biella, Carla de Agostino; Santos, Rafael Freitas dos.

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: To assess the cost-per-responder (CpR) of biologic therapies available in Brazil to treat moderate-to-severe plaque psoriasis (PsO) from the private healthcare system’s perspective. Methods: Number needed to treat (NNT) and (CpR) analyses were performed to evaluate biologic therapies’ cost...

Psoríase, Produtos Biológicos, Custos e Análise de Custo, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Economic evaluation of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare systemp

Shimabukuro Ho, Rodrigo; Sebastião, Mariana Mioti; Carvalho, João Paulo Venezian de; Neves, Tomás; Nussbaum, Micha.

J. bras. econ. saúde (Impr.); 12 (2), 2020

Objective: The aim of the study was to demonstrate the economic impact of two PD-L1 immunohistochemistry (IHC) assays, SP142 versus 22C3, in the treatment with atezolizumab plus nab-paclitaxel in patients with advanced triple negative breast cancer (aTNBC) in the Brazilian private healthcare system (BPHS...

Imuno-Histoquímica, Neoplasias de Mama Triplo Negativas, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective

Santos, Marcos; Custodio, Marcelo Graziano; Matsuo, Alisson Leonardo; Montenegro, Giuliana; Pepe, Camila; Asano, Enzo; Araujo, Luiz Henrique.

J. bras. econ. saúde (Impr.); 10 (3), 2018

Objective: Comparing the costs and effectiveness of plasma genotyping versus tumor genotyping for detecting the T790M mutation in advanced non-small cell lung cancer (NSCLC) with a mutation in the epidermal growth factor receptor (EGFR) and that progressed after use of an EGFR tyrosine kinase inhibitor (...

Carcinoma Pulmonar de Células não Pequenas, Análise Custo-Benefício, Técnicas de Genotipagem, 24479, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Análise de custo-efetividade da toxina onabotulínica A no tratamento preventivo da migrânea crônica sob a perspectiva do sistema privado de saúde do Brasil

Piovesan, Elcio; Cadecaro, Patricia; Pepe, Camila.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objetivo: Avaliar o custo-efetividade da toxina onabotulínica A (TB) versus ausência de tratamento “não tratar” (NT) da migrânea crônica refratária a pelo menos dois medicamentos em um Sistema de Saúde Suplementar. Métodos: Modelo analítico de decisão simulou desfechos e custos em 24 semana...

Análise Custo-Benefício, Cefaleia, Toxinas Botulínicas Tipo A, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Custo-efetividade de terapias anti-PD-1 comparadas com ipilimumabe para o tratamento de melanoma avançado sob a perspectiva do sistema de saúde suplementar brasileiro

Tanaka, Straus; Aratangy, Guilherme; Carelli, Guareide; Fahham, Lucas; Pepe, Camila; Bernardino, Graziela.

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objetivo: Realizar uma análise de custo-efetividade das terapias imuno-oncológicas anti-PD-1 aprovadas no Brasil versus ipilimumabe no tratamento do paciente sem tratamento prévio com melanoma metastático (estádios III ou IV), independentemente da mutação BRAF sob a perspectiva do sistema de saúd...

Análise Custo-Benefício, Melanoma, Saúde Suplementar

Texto completo (link principal)     Texto completo (link alternativo)    

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

Weschenfelder, Rui Fernando; Tsuchiya, Carolina Terumi; Kim, Hellen Soo Jin; Simões, Jairo Amorim; La Scala, Cintia Sayuri Kurokawa.

J. bras. econ. saúde (Impr.); 8 (1), 2016

Objective: To compare the treatment costs of different sequences of regimens including monoclonal antibodies in metastatic colorectal cancer (CRCm) treatment for the Brazilian Supplementary Healthcare System. Methods:  Sixteen scenarios were analyzed, each one comparing a sequence of bevacizumab TML plu...

Neoplasias Colorretais, Custos de Cuidados de Saúde, Saúde Suplementar

Texto completo